ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 3 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world's best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.
The ResMed story
In 1981 Professor Colin Sullivan and colleagues at the University of Sydney developed the first continuous positive airway pressure (CPAP) device, the first successful, non-invasive treatment for obstructive sleep apnea (OSA). In 1989 ResMed was founded to commercialize a device for treating a major subset of sleep-disordered breathing (SDB). Operations have grown dramatically in the past 25 years. Awareness about the dangers of untreated OSA has increased, and we have introduced new, highly innovative product lines. ResMed now operates in more than 100 countries via direct offices and a network of distributors.
Since 1989, we have maintained our focus on SDB, while also expanding into the fields of respiratory medicine and cardiology. We help make quality care accessible for those with diseases such as chronic obstructive pulmonary disease and cardiovascular disease.
Our Vision and Our Mission
Our vision is to be the global solutions leader for SDB, COPD and other major chronic diseases. Our mission is to improve the quality of life for patients, prevent progression of chronic diseases, and reduce overall healthcare system costs.
Aims and objectives
We are a global leader in the development, manufacturing and marketing of innovative medical products for the treatment and management of respiratory disorders, with a focus on sleep-disordered breathing.
We sell high quality products for every step of the patient pathway — from diagnosis to treatment in more than 100 countries through direct offices and a network of distributors.
We are advancing innovative technology in sleep and respiratory medicine. We incorporate this technology into innovative products that reach patients around the world. We will at all times act ethically in dealing with both customers and employees.